Navigation Links
New therapy enlists immune system to boost cure rate in a childhood cancer
Date:5/27/2009

A multicenter research team has announced encouraging results for an experimental therapy using elements of the body's immune system to improve cure rates for children with neuroblastoma, a challenging cancer of the nervous system.

John M. Maris, M.D., chief of Oncology at The Children's Hospital of Philadelphia, co-authored the phase 3 clinical trial, which was led by Alice Yu, M.D., Ph.D., of the University of California, San Diego. Maris chairs the committee supervising the trial for the Children's Oncology Group, a cooperative organization that pools resources from leading medical centers to study and devise new treatments for pediatric cancers.

Neuroblastoma, a cancer of the peripheral nervous system, usually appears as a solid tumor in the chest or abdomen. Neuroblastoma accounts for 7 percent of all childhood cancers, but due to its often aggressive nature, causes 15 percent of all childhood cancer deaths.

Yu will present the neuroblastoma study results on June 2 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Fla. In advance of the meeting, ASCO published the findings online on May 14.

Maris explained that immunotherapy for cancer involves triggering the body's immune system to attack cancer cells. Monoclonal antibodies are molecules customized to target particular cancers, while cytokines are naturally occurring signaling proteins that regulate the body's immune responses.

In the current study, Children's Oncology Group researchers studied 226 children with high-risk neuroblastoma. Half received the immunotherapy, while half received standard therapy (chemotherapy and stem cell transplantation). The patients who received the immunotherapy were 20 percent more likely than those in the standard therapy group to live disease-free two years after treatment. "This 20 percent improvement in preventing relapse led to a greater cure ratethe first substantial increase in cure rate for neuroblastoma for more than a decade," said Maris.

The researchers halted the trial earlier than expected after early results showed the benefits of immunotherapy. "This experimental immunotherapy is poised to become part of the new standard of care for children with the aggressive form of neuroblastoma," said Maris.

Maris added that the supply of the antibodies and cytokines used in the trial was limited, and that pediatric oncologists were seeking biotechnology companies to move the biological agents into commercial production to make the treatment readily available to children with neuroblastoma.


'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia
Source:Eurekalert

Related medicine news :

1. Worlds First Animatronic Animal Therapy Program Set to Open
2. What You Need to Know in Your 40s to Have a Healthy Menopause -- Without Hormone Replacement Therapy
3. Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise
4. CORRECTION: Viral Genetics Pursues Promising New Therapy for Lyme Disease With Grant from Time for Lyme, Inc.
5. Pills Plus Psychotherapy Can Beat Insomnia
6. Study Shows NeuroStar TMS Therapy(R) Improved Key Elements of Cognition in Patients with Major Depressive Disorder
7. MEDai Helps Medicare Part D Sponsors Adhere to CMS Medication Therapy Management Initiative
8. Theravive.com Expands Values Counseling and Therapy Into Michigan, Florida, and Washington State
9. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
10. Light Sciences Oncology Announces Results of Study on Immunotherapeutic Mechanism of Aptocine(TM), a Novel Light-Activated Drug Therapy for Cancer
11. FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , ... February 11, 2016 , ... “ HEALING MIND ... through a Well Managed Mind” (published by Balboa Press) teaches readers how to become ... being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding of how ...
(Date:2/11/2016)... Oregon (PRWEB) , ... February 11, 2016 , ... ... campus participated in the American Osteopathic Association’s (AOA) Match Program Tuesday, February 9, ... Match Program places students into osteopathic graduate medical education positions across the country. ...
(Date:2/11/2016)... Tampa, FL (PRWEB) , ... February 11, 2016 , ... ... Tampa Bay Lightning take on the St. Louis Blues at the Amalie Arena. The ... only portable, inflatable, walk-through heart exhibit, the MEGA Heart, prior to the game. The ...
(Date:2/11/2016)... ... , ... The president released a FY 2017 budget request on Tuesday that ... the cost burden to military beneficiaries. , MOAA’s president, retired Air Force Lt. ... including limited quantifiable benefit fixes mixed with numerous beneficiary fee hikes. , “We were ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pediatric ... to improve care by making data on heart procedures public and easily understandable ... Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes will bring ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016 Indiso ltd ... ungedeckten medizinischen Bedarf bei Lungen- und Atemwegserkrankungen ... Forschungsprogramms bekannt. Das Programm, das sich mit ... respiratorischen Funktionen und anderer klinischer Parameter. ... das sich auf den ungedeckten medizinischen Bedarf ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... , Feb. 11, 2016  Walgreens has committed ... 39 states and Washington, D.C. as ... move that was commended by shareholder advocacy organization As You ... As You Sow. "Many people hold on to unneeded drugs ... can have tragic consequences." --> Conrad MacKerron ...
Breaking Medicine Technology: